{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T20:03:00Z","timestamp":1778270580886,"version":"3.51.4"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100012557","name":"Six Talent Climax Foundation of Jiangsu","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012557","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.bmcl.2021.127909","type":"journal-article","created":{"date-parts":[[2021,3,9]],"date-time":"2021-03-09T18:59:15Z","timestamp":1615316355000},"page":"127909","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Discovery of a new class of multi-target heterocycle piperidine derivatives as potential antipsychotics with pro-cognitive effect"],"prefix":"10.1016","volume":"40","author":[{"given":"Lanchang","family":"Gao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"Hao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiali","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ru","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingkun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bi-Feng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guisen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmcl.2021.127909_b0005","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.pnpbp.2012.03.015","article-title":"Complexity and schizophrenia","volume":"45","author":"Fernandez","year":"2013","journal-title":"Prog Nueuro-Psychoph"},{"key":"10.1016\/j.bmcl.2021.127909_b0010","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1002\/med.21512","article-title":"Effects of antipsychotic drugs on neurites relevant to schizophrenia treatment","volume":"39","author":"Huang","year":"2019","journal-title":"Med Res Rev"},{"issue":"7","key":"10.1016\/j.bmcl.2021.127909_b0015","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1021\/cn400121z","article-title":"Classics in chemical neuroscience: clozapine","volume":"4","author":"Wenthur","year":"2013","journal-title":"ACS Chem Neurosci"},{"issue":"7","key":"10.1016\/j.bmcl.2021.127909_b0020","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1021\/acschemneuro.8b00159","article-title":"Classics in chemical neuroscience: risperidone","volume":"9","author":"Chopko","year":"2018","journal-title":"ACS Chem Neurosci"},{"issue":"10","key":"10.1016\/j.bmcl.2021.127909_b0025","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.3390\/ijms19103105","article-title":"Multi-target approach for drug discovery against schizophrenia","volume":"19","author":"Kondej","year":"2018","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.bmcl.2021.127909_b0030","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/pnp.430","article-title":"Pharmacological treatment of schizophrenia - a review -of progress","volume":"20","author":"Dimitrelis","year":"2016","journal-title":"Prog. Neuro-Psych"},{"issue":"5","key":"10.1016\/j.bmcl.2021.127909_b0035","doi-asserted-by":"crossref","first-page":"389","DOI":"10.2165\/00023210-200620050-00004","article-title":"Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia","volume":"20","author":"Horacek","year":"2006","journal-title":"CNS Drugs"},{"key":"10.1016\/j.bmcl.2021.127909_b0040","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s40263-020-00718-4","article-title":"Comparative tolerability of dopamine D2\/3 receptor partial agonists for schizophrenia","volume":"34","author":"Keks","year":"2020","journal-title":"CNS Drugs"},{"key":"10.1016\/j.bmcl.2021.127909_b0045","first-page":"152","article-title":"Distinct inactive conformations of the dopamine D2 and D3 receptors correspond to different extents of inverse agonism","volume":"27","author":"Lane","year":"2020","journal-title":"CNS Drugs"},{"key":"10.1016\/j.bmcl.2021.127909_b0050","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.2174\/156802608785161385","article-title":"5-HT1A receptor, an old target for new therapeutic agents","volume":"8","author":"Lacivita","year":"2008","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.bmcl.2021.127909_b0055","doi-asserted-by":"crossref","first-page":"861","DOI":"10.2174\/18715273113129990088","article-title":"Improving the treatment of schizophrenia: role of 5-HT receptors in modulating cognitive and extrapyramidal motor functions","volume":"12","author":"Ohno","year":"2013","journal-title":"CNS Neurol Disord: Drug Targets"},{"key":"10.1016\/j.bmcl.2021.127909_b0060","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1007\/s40263-020-00752-2","article-title":"Targeting serotonin 5-HT2A receptors to better treat schizophrenia: rationale and current approaches","volume":"34","author":"Kantrowitz","year":"2020","journal-title":"CNS Drugs"},{"key":"10.1016\/j.bmcl.2021.127909_b0065","doi-asserted-by":"crossref","first-page":"4671","DOI":"10.1021\/jm400408r","article-title":"Synthesis and biological investigation of coumarin piperazine (piperidine) derivatives as potential multireceptor atypical antipsychotics","volume":"56","author":"Chen","year":"2013","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2021.127909_b0070","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.ejmech.2014.01.012","article-title":"Synthesis and evaluation of new coumarin derivatives as potential atypical antipsychotics","volume":"74","author":"Chen","year":"2014","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmcl.2021.127909_b0075","doi-asserted-by":"crossref","first-page":"10017","DOI":"10.1021\/acs.jmedchem.8b01096","article-title":"Synthesis and biological evaluation of fused tricyclic heterocycle piperazine (piperidine) derivatives as potential multireceptor atypical antipsychotics","volume":"61","author":"Cao","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2021.127909_b0080","unstructured":"Dou F, Chen Y, Jing P, Qiu Y, Yu M, Zhang G, A compound for the treatment of schizophrenia and its application. CN109232549A (2019)."},{"key":"10.1016\/j.bmcl.2021.127909_b0085","doi-asserted-by":"crossref","first-page":"153","DOI":"10.2174\/156802610790411027","article-title":"Histamine H3 antagonists for treatment of cognitive deficits in CNS diseases","volume":"10","author":"Raddatz","year":"2010","journal-title":"Cur Top Med Chem"},{"issue":"1","key":"10.1016\/j.bmcl.2021.127909_b0090","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.coph.2011.01.004","article-title":"5-HT6 receptor and cognition","volume":"11","author":"Codony","year":"2011","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.bmcl.2021.127909_b0095","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/0006-8993(84)90811-4","article-title":"Distribution of the histaminergic neuron system in the central nervous system of rats; a fluorescent immunohistochemical analysis with histidine decarboxylase as a marker","volume":"295","author":"Watanabe","year":"1984","journal-title":"Brain Res"},{"key":"10.1016\/j.bmcl.2021.127909_b0100","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1124\/mol.116.104752","article-title":"The histamine H3 receptor: structure, pharmacology, and function","volume":"90","author":"Nieto-Alamilla","year":"2016","journal-title":"Mol Pharmacol"},{"issue":"1","key":"10.1016\/j.bmcl.2021.127909_b0105","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1517\/13543776.2014.848197","article-title":"New developments around histamine H3 receptor antagonists\/inverse agonists: a patent review (2010 \u2013 present)","volume":"24","author":"\u0141a\u017cewska","year":"2014","journal-title":"Expert Opin Ther Patents"},{"key":"10.1016\/j.bmcl.2021.127909_b0110","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1124\/jpet.104.078402","volume":"313","author":"Fox","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.bmcl.2021.127909_b0115","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1017\/S1461145712000739","article-title":"Preclinical evaluation of non-imidazole histamine H3 receptor antagonists in comparison to atypical antipsychotics for the treatment of cognitive deficits associated with schizophrenia","volume":"16","author":"Brown","year":"2013","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.bmcl.2021.127909_b0120","doi-asserted-by":"crossref","first-page":"3760","DOI":"10.2174\/1381612821666150605105325","article-title":"Do Histamine receptor 3 antagonists have a place in the therapy for schizophrenia?","volume":"21","author":"Ellenbroek","year":"2015","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.bmcl.2021.127909_b0125","doi-asserted-by":"crossref","unstructured":"AIto C, Histamine H3-receptor inverse agonists as novel antipsychotics. Cent Nerv Syst Agents Med Chem 2009, 9, 132-136.","DOI":"10.2174\/187152409788452036"},{"key":"10.1016\/j.bmcl.2021.127909_b0130","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2174\/157340810794578515","article-title":"Discovery of dual chemotherapy drug candidates designed by molecular hybridization","volume":"6","author":"Rodolfo","year":"2010","journal-title":"Curr Enzyme Inhib"},{"key":"10.1016\/j.bmcl.2021.127909_b0135","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ejmech.2020.112214","article-title":"Discovery of aryl-piperidine derivatives as potential antipsychotic agents using molecular hybridization strategy","volume":"193","author":"Zhu","year":"2020","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmcl.2021.127909_b0140","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1016\/j.euroneuro.2015.07.010","article-title":"Role of serotonin 5-HT2C and histamine H1 receptors in antipsychotic-induced diabetes: a pharmacoepidemiological-pharmacodynamic study in VigiBase","volume":"25","author":"Montastruc","year":"2015","journal-title":"Eur Neuropsychopharm"},{"key":"10.1016\/j.bmcl.2021.127909_b0145","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1073\/pnas.0611417104","article-title":"From the cover: antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase","volume":"104","author":"Kim","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"10.1016\/j.bmcl.2021.127909_b0150","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s00213-004-2096-z","article-title":"Dopamine D3 receptor antagonists improve the learning performance in memory-impaired rats","volume":"179","author":"Laszy","year":"2005","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.bmcl.2021.127909_b0155","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1517\/17425250903055070","article-title":"Herg-related drug toxicity and models for predicting herg liability and qt prolongation","volume":"5","author":"Raschi","year":"2009","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.bmcl.2021.127909_b0160","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2165\/00002018-200528010-00003","article-title":"Atypical antipsychotics: from potassium channels to torsade de pointes and sudden death","volume":"28","author":"Titier","year":"2005","journal-title":"Drug Saf"},{"key":"10.1016\/j.bmcl.2021.127909_b0165","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1136\/heartjnl-2017-312107","article-title":"Cardiovascular effects of psychotic illnesses and antipsychotic therapy","volume":"105","author":"Howell","year":"2019","journal-title":"Heart"},{"key":"10.1016\/j.bmcl.2021.127909_b0170","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1111\/j.1476-5381.2011.01386.x","article-title":"Animal models of schizophrenia","volume":"164","author":"Jones","year":"2011","journal-title":"Br J Pharmacol"},{"issue":"1","key":"10.1016\/j.bmcl.2021.127909_b0175","doi-asserted-by":"crossref","DOI":"10.1186\/s12888-020-02509-z","article-title":"Modulating NMDA receptors to treat MK-801-induced schizophrenic cognition deficit: effects of clozapine combining with PQQ treatment and possible mechanisms of action","volume":"20","author":"Zhou","year":"2020","journal-title":"BMC Psychiatry."},{"key":"10.1016\/j.bmcl.2021.127909_b0180","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.bbr.2012.06.031","article-title":"Evidence that conditioned avoidance responses are reinforced by positive prediction errors signaled by tonic striatal dopamine","volume":"241","author":"Dombrowski","year":"2013","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.bmcl.2021.127909_b0185","doi-asserted-by":"crossref","first-page":"358","DOI":"10.2174\/138161210790170085","article-title":"Conditioned avoidance response in the development of new antipsychotics","volume":"16","author":"Wadenberg","year":"2010","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.bmcl.2021.127909_b0190","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.bbr.2007.06.012","article-title":"Atypical antipsychotics attenuate a sub-chronic PCP-induced cognitive deficit in the novel object recognition task in the rat","volume":"184","author":"Grayson","year":"2007","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.bmcl.2021.127909_b0195","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ejmech.2017.12.099","article-title":"Synthesis and biological evaluation of a series of multi-target N-substituted cyclic imide derivatives with potential antipsychotic effect","volume":"145","author":"Xu","year":"2018","journal-title":"Eur J Med Chem"}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X21001359?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X21001359?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T07:39:28Z","timestamp":1760773168000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X21001359"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":39,"alternative-id":["S0960894X21001359"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2021.127909","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of a new class of multi-target heterocycle piperidine derivatives as potential antipsychotics with pro-cognitive effect","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2021.127909","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"127909"}}